Researchers are making strides toward understanding and detecting Alzheimer’s disease in its earliest stages, when interventions may be most effective at slowing the progress of the disease.
Ultimovacs’ melanoma vaccine fails in PhII; Regenxbio’s $140M offering
Plus, news about MindMed, Ventyx Biosciences, Rakuten Medical and Ross Acquisition Corp: Ultimovacs’ melanoma vaccine flops in PhII: When added to Bristol Myers Squibb’s Yervoy